Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chengbo Han

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
Therapeutic Advances in Medical Oncology|October 22, 2024
Expert consensus on the use of third-generation EGFR-TKIs in EGFR-mutated advanced non-small cell lung cancer with various T790M mutations post-resistance to first-/second-generation EGFR-TKIsJietao Ma, Letian Huang, Chengbo Han
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|March 13, 2018
[Research Advances of Pan-negative Type of Non-small Cell Lung Cancer]Li Sun, Zhicheng Xiong, Chengbo Han
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|September 16, 2010
[Comparison of EGFR and KRAS status between primary non-small cell lung cancer and corresponding metastases: a systematic review and meta-analysis]Chengbo Han, Huawei Zou, Jietao Ma, et al.
JCO Precision Oncology|July 10, 2025
Immune Checkpoint Inhibitors in Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Resistant Chemotherapy-Naïve Advanced Non-Small Cell Lung Cancer: A Meta-Analysis Based on Eight Randomized TrialsLetian Huang, Shuling Zhang, Li Sun, et al.
Cancer Investigation|October 21, 2011
EGFR mutations, gene amplification, and protein expression and KRAS mutations in primary and metastatic tumors of nonsmall cell lung cancers and their clinical implications: a meta-analysisChengbo Han, Jietao Ma, Jianzhu Zhao, et al.
Frontiers of Medicine in China|February 22, 2014
MSI/LOH and extron expression of the FHIT gene in gastric carcinomaYuping Xiao, Lili Mao, Chengbo Han, et al.
Current Treatment Options in Oncology|May 8, 2025
Immunotherapy-Boosted Stereotactic Ablative Radiotherapy in Inoperable Early-Stage Non-Small Cell Lung CancerJie Lian, Li Sun, Shuling Zhang, et al.
Journal of Thoracic Disease|June 16, 2017
Benefits of postoperative thoracic radiotherapy for small cell lung cancer subdivided by lymph node stage: a systematic review and meta-analysisShuling Zhang, Xin Sun, Li Sun, et al.
JTO Clinical and Research Reports|January 29, 2025
Impact of Prophylactic Use of PEG-rhG-CSF on First-Line Immunochemotherapy in Advanced NSCLC: A Cohort StudyLi Sun, Yuan Tian, Shuling Zhang, et al.
Scientific Reports|October 2, 2024
First-line treatment of EGFR-mutated non-small cell lung cancer with brain metastases: a systematic review and meta-analysisJietao Ma, Xiaoxue Pang, Shuling Zhang, et al.
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
Therapeutic Advances in Medical Oncology|October 22, 2024
Expert consensus on the use of third-generation EGFR-TKIs in EGFR-mutated advanced non-small cell lung cancer with various T790M mutations post-resistance to first-/second-generation EGFR-TKIsJietao Ma, Letian Huang, Chengbo Han
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|March 13, 2018
[Research Advances of Pan-negative Type of Non-small Cell Lung Cancer]Li Sun, Zhicheng Xiong, Chengbo Han
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|September 16, 2010
[Comparison of EGFR and KRAS status between primary non-small cell lung cancer and corresponding metastases: a systematic review and meta-analysis]Chengbo Han, Huawei Zou, Jietao Ma, et al.
JCO Precision Oncology|July 10, 2025
Immune Checkpoint Inhibitors in Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Resistant Chemotherapy-Naïve Advanced Non-Small Cell Lung Cancer: A Meta-Analysis Based on Eight Randomized TrialsLetian Huang, Shuling Zhang, Li Sun, et al.
Cancer Investigation|October 21, 2011
EGFR mutations, gene amplification, and protein expression and KRAS mutations in primary and metastatic tumors of nonsmall cell lung cancers and their clinical implications: a meta-analysisChengbo Han, Jietao Ma, Jianzhu Zhao, et al.
Frontiers of Medicine in China|February 22, 2014
MSI/LOH and extron expression of the FHIT gene in gastric carcinomaYuping Xiao, Lili Mao, Chengbo Han, et al.
Current Treatment Options in Oncology|May 8, 2025
Immunotherapy-Boosted Stereotactic Ablative Radiotherapy in Inoperable Early-Stage Non-Small Cell Lung CancerJie Lian, Li Sun, Shuling Zhang, et al.
Journal of Thoracic Disease|June 16, 2017
Benefits of postoperative thoracic radiotherapy for small cell lung cancer subdivided by lymph node stage: a systematic review and meta-analysisShuling Zhang, Xin Sun, Li Sun, et al.
JTO Clinical and Research Reports|January 29, 2025
Impact of Prophylactic Use of PEG-rhG-CSF on First-Line Immunochemotherapy in Advanced NSCLC: A Cohort StudyLi Sun, Yuan Tian, Shuling Zhang, et al.
Scientific Reports|October 2, 2024
First-line treatment of EGFR-mutated non-small cell lung cancer with brain metastases: a systematic review and meta-analysisJietao Ma, Xiaoxue Pang, Shuling Zhang, et al.
Pageof 3